Speak directly with our senior bankers to understand your strategic options. Confidential, no obligation.
Investment Banks for Healthcare Deals
July 11, 2026
We analyzed eight leading healthcare M&A advisory firms serving middle-market sellers: founder-owned practices and PE-backed platforms with enterprise values between $20M–$1B. These firms represent many of the most visible advisory brands healthcare owners encounter when exploring a sale. This article reflects our opinions, based generally on market reputation and our analysis of publicly available information.
How We Evaluated These Firms
Not all investment banks are built for the same kind of deal. For middle-market healthcare sellers, especially founder-owned practices or PE-backed platforms in the $20M–$1B range, the firm you choose has an outsized effect on the outcome. We evaluated each bank across five factors that matter most to this seller profile:
1. Healthcare Deal Volume & Recency
A bank’s track record only matters if it reflects the market today. Buyer appetite, valuations, and deal structures shift with reimbursement policy and sponsor cycles, so look for closed transactions in the past 18–24 months, deals in your specific subsector, and senior bankers actively running live mandates, not a resume built on a different market environment.
2. Middle-Market Focus & Deal Size Alignment
At a firm built for $500M deals, a $50M transaction often gets handed to junior staff. At a purpose-built lower middle-market boutique, it gets principal-level attention from start to finish. For founder-led sellers especially, that difference shows up in the quality of buyer outreach, the precision of your CIM, and how well your banker can articulate your business’s value in real time.
3. Healthcare Subsector Coverage
Healthcare is not one market. Physician services, behavioral health, HCIT, diagnostics, and pharma services each have distinct buyer universes and valuation frameworks. A bank with genuine subsector depth can map your business to the right buyers and frame the story correctly, rather than running generic outreach to buyers who won’t understand your model.
4. Buyer Network Strength (PE & Strategics)
The quality of your buyer pool determines your leverage. A bank with deep, current relationships can surface buyers others miss, including emerging platform builders or funds actively deploying in your space. Just as important is the ability to create competitive tension: the best outcomes come from multiple credible buyers engaged simultaneously, not a single interested party.
5. Process Transparency & Thought Leadership
The right advisor doesn’t just run the process; they educate you through it, setting realistic expectations and giving you the information you need to make good decisions at each stage. Firms that publish regular market commentary tend to stay sharper on what buyers are actually prioritizing, so their guidance reflects real, current conversations rather than outdated assumptions.
Disclaimer: This analysis reflects our opinion based on publicly available information and market research. It is for informational purposes only, does not constitute investment advice, and does not guarantee outcomes. Readers should conduct their own due diligence when selecting an investment bank.
Investment Banks for Healthcare Deals
| Firm | Good Fit For |
| FOCUS Investment Banking | Founder-led and PE-backed middle-market healthcare exits from $20M to $200M |
| Houlihan Lokey | High-volume mid-market processes, global sponsor coverage. Best for larger PE-backed groups. |
| KeyBanc Capital Markets (Cain Brothers) | Provider-heavy and healthcare services, HCIT-heavy mandates |
| Harris Williams | Sponsor-backed healthcare services and tech-enabled models |
| Robert W. Baird & Co. | Relationship-driven mid-market advisory with broad healthcare reach |
| Rothschild & Co. | Europe-forward mandates, independence-driven advisory |
| J.P. Morgan | Mega-deals and complex global strategic transactions |
| ConAlliance | European mid-market healthcare; cross-border boutique processes |
Investment Banks for Healthcare Deals: Descriptions & Reviews
FOCUS Investment Banking is built for sell-side execution. The team focuses on founder-owned and smaller private equity–backed healthcare businesses and runs a senior-led “quarterback” process. FOCUS has closed 130+ transactions over the last decade, including recent healthcare transactions in provider services, animal health, distribution, pharmacy, laboratory and diagnostics, and healthcare technology. The firm is particularly active in provider services, and is one of the leading advisors to physician groups.
- Healthcare deal volume & recency: Active in current-market healthcare sell-side work with repeat execution across subsectors.
- Middle-market alignment: Purpose-built for mid-market companies where senior attention and process control drive outcomes.
- Subsector coverage: Broad coverage across physician services, behavioral health, and other services and technology sectors.
- Buyer network strength: Deep relationships with healthcare-focused PE and strategic consolidators.
- Process transparency & thought leadership: Senior-led, seller-education approach and ongoing market visibility through updates and content.
| Summary of Online Reviews |
|---|
| Clients often describe FOCUS’s healthcare team as patient, highly responsive, and clear in how they explain each step of the process. One seller shared, “As physicians, there’s a lot we don’t fully understand about the business world. [The FOCUS team] was patient and did a great job explaining things throughout the transaction. I highly recommend working with them.” |
Houlihan Lokey is one of the most active healthcare M&A advisors globally in the sub-$1B market. Its advantage is deal volume, repeatable process management, and broad coverage that allows it to run competitive auctions across many healthcare business models.
- Healthcare deal volume & recency: Top-tier pace and consistent closing activity in healthcare mid-market
- Middle-market alignment: Strong fit for scaled mid-market processes, more institutional than boutique
- Subsector coverage: Very broad across healthcare services, devices, HCIT, and life sciences-adjacent services
- Buyer network strength: Extensive sponsor and strategic reach driven by constant market activity
- Process transparency & thought leadership: Structured process and regular sector commentary
| Summary of Online Reviews |
|---|
| Clients often describe Houlihan Lokey’s healthcare team as highly effective at driving competitive outcomes, frequently noting “outstanding results and a superior service level.” Sellers, particularly private equity–backed companies, highlight the firm’s ability to identify every relevant buyer and create bidding tension, with one CEO noting they “created a bidding war” that exceeded expectations. |
KeyBanc Capital Markets (Cain Brothers)
Cain Brothers is healthcare-focused and long-tenured in provider-heavy subsectors. It is often chosen when the seller wants a healthcare-only team that can speak fluently across provider dynamics and reimbursement complexity.
- Healthcare deal volume & recency: High recent activity with consistent healthcare transaction flow
- Middle-market alignment: Excellent fit for middle-market healthcare transactions and complex provider situations
- Subsector coverage: Strong across providers, payors, HCIT, life sciences tools, and services
- Buyer network strength: Deep ties with health systems and PE-backed consolidators
- Process transparency & thought leadership: Known for preparation quality and clear process management
| Summary of Online Reviews |
|---|
| Clients often describe Cain Brothers as “industry insiders” who bring “deep industry knowledge” and a “holistic viewpoint” that clarifies strategic options. Sellers also note that the team runs a “highly professional sale process” and leverages “extensive buyer relationships” to secure multiple strong offers, resulting in outcomes that exceed expectations. |
Harris Williams is a middle-market M&A advisor known for running competitive sell-side processes, often for sponsor-backed assets. It tends to perform best when the objective is broad buyer outreach and strong competitive tension in a defined timeline.
- Healthcare deal volume & recency: Strong recent flow in healthcare services and tech-enabled models
- Middle-market alignment: Excellent fit for $250M–$1B+ processes where dealcraft and pacing matter
- Subsector coverage: Broad, with particularly strong services, outsourcing, HCIT, and pharma-services adjacency
- Buyer network strength: Strong sponsor relationships and effective strategic outreach
- Process transparency & thought leadership: Process-forward, highly structured execution with credible market insight
| Summary of Online Reviews |
|---|
| Clients often describe Harris Williams as “phenomenal” partners who run a “structured, highly professional process” and deliver results that “exceed expectations.” Sellers consistently point to the firm’s sector knowledge, global buyer network, and high-caliber advice as instrumental in securing multiple strong offers and finding the right long-term partner. |
Baird is an employee-owned bank with broad healthcare coverage and a relationship-forward style. It is often a fit for teams that want steady process management and access to a wide buyer universe.
- Healthcare deal volume & recency: Consistent healthcare activity and steady transaction cadence
- Middle-market alignment: Excellent for mid-market sellers who value partner-style advisory
- Subsector coverage: Broad across HCIT, services, provider models, and biotech-adjacent categories
- Buyer network strength: Strong access to sponsors and strategics through a wide platform reach
- Process transparency & thought leadership: Collaborative process orientation and market insight sharing
| Summary of Online Reviews |
|---|
| Clients often describe Baird as a “true partnership” built on deep sector knowledge and an extensive industry network, noting that the team “knew all the key players” and kept them informed at every step. Sellers also highlight that Baird’s frequent dialogue with industry investors ensured “no stone was left unturned,” while still tailoring the process to fit the company’s culture. |
Rothschild is a global advisory firm with strong European depth and an independence-driven model. It can be a strong option for European healthcare mandates or cross-border work where an independent advisor is preferred.
- Healthcare deal volume & recency: Strong, especially in Europe and broader EMEA activity
- Middle-market alignment: Good for mid and upper-mid mandates
- Subsector coverage: Broad across healthcare sectors, often strongest where Europe has dense strategic buyers
- Buyer network strength: Strong corporate and PE relationships with a Europe-weighted tilt
- Process transparency & thought leadership: Process is typically high-touch, thought leadership is less public-facing
| Summary of Online Reviews |
|---|
| Clients often describe Rothschild as providing unbiased, client-first advice backed by deep regional expertise and a powerful network. One European healthcare CEO noted that Rothschild’s “long-standing presence and network gave us confidence,” adding that the firm delivered “both a high-value outcome and a smooth process.” |
J.P. Morgan is a global bulge-bracket leader that dominates large-cap healthcare M&A. Its best fit is mega-deals, public-company transactions, and complex cross-border mandates where scale, financing capability, and global reach matter most.
- Healthcare deal volume & recency: Excellent in high-value transactions
- Middle-market alignment: Low for founder-led mid-market exits; more focused on large PE and bulge bracket clients
- Subsector coverage: Extremely broad across pharma, biotech, devices, payors, and systems
- Buyer network strength: Exceptional for global strategics and mega-funds
- Process transparency & thought leadership: Strong research visibility and conference leadership
| Summary of Online Reviews |
|---|
| Large healthcare clients often praise J.P. Morgan for its “sophisticated financing solutions” and “unparalleled global access,” particularly on complex, cross-border transactions. At the same time, some middle-market sellers note that the firm is “focused on strategic, large-cap mandates,” which can translate into a more institutional, less personalized experience for smaller deals. |
If you’d like to learn more about our healthcare investment banking services, reach out to Eric here.
Learn More About Our ServicesWritten by
Eric Yetter
Managing Director
Eric Yetter is an investment banker focused on healthcare provider services. Eric has completed a variety of healthcare transactions, many with private equity firms and PE-backed companies. His past clients include leading physician and dental groups, behavioral health companies, healthcare facilities, and institutional healthcare investors.
View Bio
Written by
Managing Director
Related Insights
Let's connect
M&A guidance, backed by real experience
Whether you’re exploring a sale, raising capital, or simply want an outside perspective on where your business stands, our bankers are ready to listen. Reach out to start a confidential conversation with the FOCUS team.
